| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 140.789 | 197.921 | 265.329 | 266.764 | 278.283 | 372.387 | 415.374 | 493.625 | 573.970 | 646.197 |
| Total Income - EUR | 149.473 | 206.182 | 278.556 | 279.730 | 296.575 | 410.272 | 452.379 | 544.155 | 612.913 | 682.150 |
| Total Expenses - EUR | 140.542 | 188.350 | 252.511 | 243.767 | 277.079 | 362.300 | 409.544 | 503.115 | 548.203 | 619.499 |
| Gross Profit/Loss - EUR | 8.931 | 17.832 | 26.045 | 35.962 | 19.497 | 47.972 | 42.835 | 41.040 | 64.710 | 62.651 |
| Net Profit/Loss - EUR | 7.474 | 15.319 | 22.885 | 33.168 | 16.636 | 44.425 | 39.455 | 36.820 | 59.135 | 54.848 |
| Employees | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Check the financial reports for the company - Omnapharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 21.701 | 26.312 | 23.597 | 21.108 | 38.517 | 36.160 | 40.831 | 40.571 | 44.072 | 41.910 |
| Current Assets | 54.155 | 75.453 | 89.478 | 101.391 | 100.011 | 142.528 | 163.737 | 163.491 | 196.425 | 246.891 |
| Inventories | 26.840 | 40.452 | 44.457 | 52.085 | 50.211 | 82.451 | 90.006 | 85.452 | 118.656 | 136.458 |
| Receivables | 17.602 | 13.254 | 33.703 | 41.086 | 38.153 | 54.984 | 60.405 | 69.897 | 68.393 | 75.229 |
| Cash | 9.713 | 21.748 | 11.318 | 8.220 | 11.647 | 5.093 | 13.326 | 8.142 | 9.375 | 35.204 |
| Shareholders Funds | 38.744 | 28.791 | 52.084 | 62.806 | 57.345 | 80.009 | 97.474 | 110.263 | 142.783 | 163.659 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 37.112 | 72.975 | 60.991 | 59.693 | 82.172 | 99.238 | 107.339 | 93.799 | 97.714 | 125.142 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Omnapharm Srl